Comparison of the effects of raloxifene and anastrozole on experimental endometriosis
article
OA: closed
CC0
⤵ 44 in-corpus citations
AI-generated summary
This study compared raloxifene and anastrozole's effects on experimental endometriosis in a preclinical model.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ObjectiveTo compare the efficacies of anastrozole and raloxifene on endometriosis.Study designA randomized, placebo-controlled, single-blind, experimental study was performed on 45 adult Wistar female rats in the Experimental Surgery Laboratory at Ondokuz Mayis University in Turkey. Endometrial tissues were implanted on the abdominal peritoneum in 45 rats. Six weeks later, the implant volumes were measured (volume-1) by performing a second laparotomy. Rats were randomized to one of three equal study groups. Saline solution (0.1 cc/rat/week, subcutaneously) was administered to group 1 (control group), anastrozole (0.004 mg/rat/day, orally) to group 2 (anastrozole group), and raloxifene (0.24 mg/rat/day, orally) to group 3 (raloxifene group) for 8 weeks. At the end of administration, a third laparotomy was performed to remeasure implant volumes (volume-2), and implants were totally excised for histopathologic examination. Volume-1 and volume-2 within the groups, as well as stromal and glandular tissues between the groups, were compared.Result(s)In the anastrozole and raloxifene groups, volume-2 values were significantly lower than those of volume-1. When compared to the control group, in both anastrozole and raloxifene groups, while glandular tissue scores were found significantly lower, stromal tissue scores were not different than that of the control group. There was no significant difference between both the GT and ST scores of the anastrozole and raloxifene groups.Conclusion(s)Anastrozole and raloxifene were seen to have caused equally the regression of the experimental endometriosis statistically significantly.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (15)
- Anastrazole and oral contraceptives: a novel treatment for endometriosis via openalex
- Effect of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats via openalex
- Genetic or Enzymatic Disruption of Aromatase Inhibits the Growth of Ectopic Uterine Tissue via openalex
- Genetic or Enzymatic Disruption of Aromatase Inhibits the Growth of Ectopic Uterine Tissue via openalex
- Genistein causes regression of endometriotic implants in the rat model via openalex
- Return of Chronic Pelvic Pain From Endometriosis After Raloxifene Treatment via openalex
- Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study via openalex
- The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial via openalex
- The role of selective oestrogen receptor modulators in the treatment of endometrial bleeding in women using long-acting progestin contraception via openalex
- [The therapy of endometriosis. New prospects]. via openalex
- Treatment of Severe Postmenopausal Endometriosis With an Aromatase Inhibitor via openalex
- Validation of Rat Endometriosis Model by Using Raloxifene as a Positive Control for the Evaluation of Novel SERM Compounds via openalex
- W2326246052 via openalex
- W2131184855 via openalex
- W1970690912 via openalex
Cited by (44)
- Epigenetics' responsibility in endometriosis: A comprehensive assessment 2025
- Progesterone resistance in endometriosis: A pathophysiological perspective and potential treatment alternatives 2024
- A review of phase II and III drugs for the treatment and management of endometriosis 2023
- Novel pharmacological therapies for the treatment of endometriosis 2022
- Advances in targeting estrogen synthesis and receptors in patients with endometriosis 2022
- Selective oestrogen receptor modulators (SERMs) for endometriosis 2021
- Role of medical treatment of endometriosis 2021
- New Therapeutics in Endometriosis: A Review of Hormonal, Non-Hormonal, and Non-Coding RNA Treatments 2021
- Endometriosis and nuclear receptors 2019
- Endometriosis - Review Of Current Therapeutic Aproaches For Disease Control 2019
- A comprehensive review of hormonal and biological therapies for endometriosis: latest developments 2019
- New insights into the efficacy of <scp>SR</scp>‐16234, a selective estrogen receptor modulator, on the growth of murine endometriosis‐like lesions 2018
- From pathogenesis to clinical practice: Emerging medical treatments for endometriosis 2018
- Current and emerging treatment options for endometriosis 2018
- Effects of silymarin, cabergoline and letrozole on rat model of endometriosis 2018
- Tratamientos farmacológicos de la endometriosis (a excepción de la adenomiosis) 2018
- New insights on the pathogenesis of endometriosis and novel non-surgical therapies 2018
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? 2018
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial 2017
- Effect of alpha‐lipoic acid on endometrial implants in an experimental rat model 2017
- Time to redefine endometriosis including its pro-fibrotic nature 2017
- Die medikamentöse Therapie der Patientin mit Endometriose 2017
- Investigational Medical Therapies for Endometriosis: Current Data and Future Trends 2017
- New developments in the medical treatment of endometriosis 2017
- SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial. 2017
- Treatment of Endometriosis with Non-Hormonal Agents: Review 2016
- The Non-Ergot Derived Dopamine Agonist Quinagolide as an Anti-Endometriotic Agent 2016
- The Protective Role of Dexpanthenol on the Endometrial Implants in an Experimentally Induced Rat Endometriosis Model 2016
- An overview of early drug development for endometriosis 2015
- Experimental Treatments of Endometriosis 2015
- Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model 2014
- Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys 2014
- The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis 2014
- Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain 2014
- Selective estrogen receptor modulators (SERMs) for endometriosis 2014
- Apoptosis in Endometriosis 2014
- New trends for the medical treatment of endometriosis 2012
- The emerging use of aromatase inhibitors for endometriosis treatment 2011
- Are aromatase inhibitors effective in endometriosis treatment? 2011
- Innovations in conservative endometriosis treatment: an updated review. 2011
- Potential cures for endometriosis 2011
- Apoptosis and endometriosis 2010
- 10.1016/s0246-1064(17)67531-5 2000
Source provenance
- europepmc
- last seen: 2026-08-09T06:10:49.860119+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:17:18.915199+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK